AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27101669
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment (glucocorticoid nasal spray)
Trial: 23815304
Drug: Psychoeducational computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational computer-based treatment
Trial: 9230790
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (500 mg over five days)
Trial: 9230790
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (750 mg over seven days)
Trial: 9230790
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment of oral artemether (600 mg) followed by mefloquine (1,250 mg)
Trial: 3319349
Drug: Sulindac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (200 mg b.i.d.)
Trial: 19835754
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement and provisionalization
Trial: 23423595
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without compression treatment
Trial: 15504185
Drug: Ketobemidone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketobemidone (1 mg ml(‐1))
Trial: 15504185
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg ml(‐1))
Trial: 8362431
Drug: Control (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (aspirin therapy)
Trial: 8362431
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aspirin therapy)
Trial: 2869952
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg to 60 mg once daily)
Trial: 2869952
Drug: Acebutolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (200 mg to 600 mg once daily)
Trial: 24657310
Drug: Family-based exposure/response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based exposure/response prevention therapy (E/RP)
Trial: 21104944
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream 0.05% (Finalgon® CPDWärmecreme)
Trial: 18182416
Drug: Dihydrocodeine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine (240 mg)
Trial: 12969694
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogen alone or with alendronate
Trial: 12969694
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen alone or with alendronate
Trial: 12969694
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy plus alendronate
Trial: 6221247
Drug: Prednisone 1
RxNorm normalized name: prednisone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1 mg/kg/24 h for one month, then decreasing dosage; cyclophosphamide 2 mg/kg/24 h if failure at one month
Trial: 6221247
Drug: Prednisone with
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone with 3 plasma exchanges over a 10-day period, continued weekly if required
Trial: 24518158
Drug: T‐cell depleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T‐cell depleting induction therapy
Trial: 12144587
Drug: Alosetron (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (1-4 mg b.d.)
Trial: 7378008
Drug: Other nonprescription
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other nonprescription decongestant preparations
Trial: 27816940
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment (mean daily dose: 18.1 mg)
Trial: 26606435
Drug: HYC‐24L (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYC‐24L (24 mg/mL of hyaluronic acid, 0.3% lidocaine)
Trial: 26606435
Drug: CPM‐22.5 (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM‐22.5 (22.5 mg/mL of hyaluronic acid)
Trial: 24338168
Drug: Low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemcitabine (250 mg/m(2)) 6-h infusion on days 1 and 8, and cisplatin (70 mg/m(2)) on day 2 every 21-day cycle (arm 1)
Trial: 24338168
Drug: Standard-dose gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose gemcitabine (1,250 mg/m(2)) 30-min infusion on days 1 and 8, with the same dose of cisplatin (arm 2)
Trial: 19204651
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) paroxetine
Trial: 17458644
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg IV (group O)
Trial: 17458644
Drug: lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam 8 mg IV (group L)
Trial: 17458644
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 2 ml IV (group P)
Trial: 15700725
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg plus zolpidem 0 mg
Trial: 15700725
Drug: Zolpidem 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 20 mg plus melatonin 0 mg
Trial: 15700725
Drug: Melatonin 0
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0 mg plus zolpidem 0 mg
Trial: 21158908
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg alone
Trial: 9535248
Drug: PncD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncD vaccine (1, 3, or 10 microg)
Trial: 9535248
Drug: PncD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncD vaccine
Trial: 2645503
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg nandrolone decanoate (ND) intramuscularly every 3 weeks for 1 year
Trial: 2645503
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections every 3 weeks for 1 year
Trial: 28045314
Drug: CPP‐ACP paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP‐ACP paste (GC Tooth Mousse) applied at each monthly orthodontic follow‐up examination
Trial: 28045314
Drug: Routine orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine orthodontic treatment (control group)
Trial: 18362870
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL (150 to 300 mg/day)
Trial: 18362870
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 to 20 mg/day)
Trial: 12725705
Drug: Rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 2 mg twice daily (R4 + SU)
Trial: 12725705
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg twice daily (R8 + SU)
Trial: 9043007
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg four times daily
Trial: 9043007
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg four times daily
Trial: 9043007
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg twice daily
Trial: 17404739
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: four doses of 20 ml 40% w/v barium sulphate
Trial: 17404739
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: three doses of 20 ml 40% w/v barium sulphate
Trial: 17404739
Drug: Regimen C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C: three doses of 20 ml 40% w/v barium sulphate plus 220 ml 2.1% barium sulphate
Trial: 17404739
Drug: Regimen D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D: three doses of 20 ml 40% w/v barium sulphate plus 15 ml diatriazoate megluamine
Trial: 17404739
Drug: Reduced-laxative CTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-laxative CTC
Trial: 15470825
Drug: L-threodops (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threodops (200 mg orally 2 hours before each session) with physical therapy (PT) and occupational therapy (OT) for 2 months, 3 days a week.
Trial: 15470825
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received PT and OT for 4 months without L-threodops.
Trial: 29556709
Drug: 11+ injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11+ injury prevention program (High Compliance, > 40 doses/season)
Trial: 29556709
Drug: 11+ injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11+ injury prevention program (Moderate Compliance, 20-39 doses/season)
Trial: 29556709
Drug: 11+ injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11+ injury prevention program (Low Compliance, 1-19 doses/season)
Trial: 26476719
Drug: Morphine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (20 mg/10 ml)
Trial: 26476719
Drug: Ketamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (50 mg + morphine 10 mg/10 ml)
Trial: 26476719
Drug: Saline (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9 % 10 ml)
Trial: 24852042
Drug: Guselkumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (various doses)
Trial: 19874691
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + Glutamine 10g tid
Trial: 15373927
Drug: Desmopressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (2 microg intravenous dose)
Trial: 11772354
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of artemether and praziquantel
Trial: 7526096
Drug: Hepatic-artery infusion
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic-artery infusion of floxuridine
Trial: 3662274
Drug: Lovastatin 5
RxNorm normalized name: niacin/lovastatin 500 mg-20 mg ORAL TABLET,EXTENDED RELEASE MULTIPHASE 24 HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 5 to 40 mg twice daily or 20 to 40 mg once daily in the evening
Trial: 31848609
Drug: Whole walnuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole walnuts diet (WD; 57-99 g/d walnuts; 2.7% ALA)
Trial: 29122636
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a history of falling (both treatments)
Trial: 28042631
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ordinary treatment only)
Trial: 25300690
Drug: L 1,2
RxNorm normalized name: glyceryl 1,2-dioleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L 1,2 group (N = 26)
Trial: 25300690
Drug: L 2,3
RxNorm normalized name: Catechol 2,3-dioxygenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L 2,3 group (N = 29)
Trial: 25300690
Drug: L 3,4
RxNorm normalized name: 2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L 3,4 group (N = 27)
Trial: 23479319
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg sodium selenite and 30 mg/kg ascorbic acid every 24 h for 4 weeks
Trial: 16932894
Drug: Tonsillectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillectomy plus pulse therapy (prednisolone, warfarin, dipyridamole, methylprednisolone pulse)
Trial: 16932894
Drug: PWDM (prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWDM (prednisolone, warfarin, dipyridamole, mizoribine)
Trial: 16932894
Drug: Tonsillectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillectomy plus pulse therapy
Trial: 10778867
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 20% with heparin (0.4 U/kg body weight/min)
Trial: 10778867
Drug: Control infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control infusion of saline (150 mmol/L)
Trial: 2871784
Drug: Bevantolol 100
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 100 to 400 mg/day
Trial: 29231498
Drug: Abdominal acupuncture
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal acupuncture therapy applied to Zhongwan (CV 12), Xiawan (CV 10), Qihai (CV 6), Guanyuan (CV 4), Tianshu (ST 25) and Shuidao (ST 28), once a day, 5 times a week for 3 months
Trial: 23461703
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) and Supportive Listening
Trial: 18074229
Drug: Pearl barley
RxNorm normalized name: Pearl barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pearl barley with high beta-glucan content (7.0 g beta-glucan per day)
Trial: 16478760
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptives with 20, 30 or 50 microg/day estrogen
Trial: 8295082
Drug: Minimal‐treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal‐treatment control
Trial: 31777325
Drug: Chronic Opioid
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic Opioid Therapy (COT) tapering trial
Trial: 2453895
Drug: Buprenorphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.2 mg)
Trial: 20651023
Drug: Cysteine plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine plasma levels after 6 months of CPAP therapy
Trial: 17846331
Drug: TP10 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP10 (5 mg/kg dose as a 30-minute intravenous infusion before surgery)
Trial: 17846331
Drug: Placebo (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (as a 30-minute intravenous infusion before surgery)
Trial: 12541863
Drug: Local group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local group (local injected with IL‐2 + radiotherapy + chemotherapy)
Trial: 12541863
Drug: General group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General group (ivdrip with IL‐2 + radiotherapy + chemotherapy)
Trial: 12541863
Drug: Convention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convention group (radiotherapy + chemotherapy)
Trial: 9555769
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous beta-blocker administration
Trial: 9555769
Drug: Oral beta-blocker
RxNorm normalized name: beta carotene Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta-blocker therapy
Trial: 9555769
Drug: Nitrates and
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates and lisinopril treatment
Trial: 2499700
Drug: DPT -
RxNorm normalized name: Diphtheria, Pertussis, Tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT - IPV (combined DPT - enhanced injectable polio vaccine)
Trial: 2499700
Drug: DPT (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT (Conventional Schedule with 3 doses of oral polio vaccine and 2 doses of DPT)
Trial: 2499700
Drug: DPT -
RxNorm normalized name: Diphtheria, Pertussis, Tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT - IPV or DPT vaccine alone
Trial: 28719572
Drug: Constraint-Induced Aphasia
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Aphasia Therapy (CIAT)
Trial: 22126550
Drug: Taxotere plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere plus poldine intravenous chemotherapy (A1)
Trial: 22126550
Drug: Taxotere intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (A2)
Trial: 22126550
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus poldine intravenous chemotherapy (B1)
Trial: 22126550
Drug: Paclitaxel intravenous
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (B2)
Trial: 11465092
Drug: Intermittent IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent IL-2 therapy
Trial: 10700435
Drug: Arthrocentesis (synovial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis (synovial fluid aspiration) before injecting 20 mg triamcinolone hexacetonide
Trial: 10700435
Drug: No arthrocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No arthrocentesis before injecting 20 mg triamcinolone hexacetonide
Trial: 2995755
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy under hyperbaric oxygenation (HBO)
Trial: 22019031
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of low dose chemoprophylaxis
Trial: 24461900
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 4 weeks
Trial: 1692612
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine surfactant therapy
Trial: 57131
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of antigen D in alginate
Trial: 29627897
Drug: Cefiderocol 2
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2 g every 8 h with 3-h infusion (3, 6, and 9 doses with furosemide, metformin, and rosuvastatin respectively)
Trial: 24659610
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements (10 supplements daily including 100 mg resveratrol, 800 mg each of green, black, and white tea extract, 250 mg pomegranate extract, 650 mg quercetin, 500 mg acetyl-l-carnitine, 600 mg lipoic acid, 900 mg curcumin, 1 g sesamin, 1.7 g cinnamon bark extract, and 1.0 g fish oil)
Trial: 24659610
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily multivitamin/mineral supplement)
Trial: 22551128
Drug: Low-dose radioiodine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radioiodine (1.1 GBq [30 mCi])
Trial: 22551128
Drug: High-dose radioiodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radioiodine (3.7 GBq [100 mCi])
Trial: 10566623
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone withdrawal
Trial: 22551128
Drug: Low-dose radioiodine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radioiodine plus thyrotropin alfa
Trial: 22551128
Drug: High-dose radioiodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radioiodine plus thyroid hormone withdrawal
Trial: 22551128
Drug: High-dose radioiodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radioiodine plus thyrotropin alfa
Trial: 18386209
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatments; specific treatments not detailed in the abstract.
Trial: 15970422
Drug: Self-administered breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered breathing exercises (intermediary outcome parameter).
Trial: 12947065
Drug: BAY 12‐9566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 12‐9566 800 mg orally bid continuously
Trial: 12947065
Drug: gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1,000 mg/m2 intravenously on specified days